bioMrieux has released its quarterly business review for the six months ended June 30, 2017. Consolidated sales rose to '1134 million for the first six months of 2017, up from '1001 million in the same period in 2016, representing a growth of 13.3 percent, including a positive currency effect of around '21 million. Organic growth (at constant exchange rates and scope of consolidation) came to 11.3 percent year-on-year (y-o-y), with FilmArray accounting for more than half of the increase.
Second-quarter sales rose 9.1 percent in the same period of 2016 with one less billing day, consolidating the 13.7 percent increase reported in the three months to March 31, 2017. This vigorous growth was powered by strong sales dynamics across all regions and particularly North America, which continued to post strong growth over the quarter.
Sales of clinical applications, which account for approximately 81 percent of the consolidated total, rose by 11.2 percent y-o-y to '457 million for the quarter and by 12.8 percent to '917 million for the first half. Sales of industrial applications, which represent around 18 percent of the consolidated total, amounted to '102 million in second-quarter 2017, up 6.4 percent on the three months to June 30, 2016 after a remarkable performance in Q1. Sales ended the first half at '202 million, up more than 10 percent y-o-y.
Sales of reagents and services rose 9.1 percent and accounted for some 90 percent of total sales. Instrument sales were up 9.2 percent. The installed base at June 30, 2017 stood at approximately 89,400 instruments, including 4800 FilmArray units. This represented an increase of 2500 new instruments over the 6-month period, including around 800 FilmArray units.